FDA warns GLP-1 drugs Ozempic, Mounjaro may raise risk of serious eye condition

The FDA issued a warning that GLP-1 medications, including Ozempic and Mounjaro, may increase the risk of a serious eye condition, likely non-arteritic anterior ischemic optic neuropathy (NAION). This is a regulatory safety signal that could affect prescribing patterns and manufacturer liability, though the absolute risk remains low and causality is not established.

AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works